高龄非瓣膜病性房颤应用华法林抗凝治疗的疗效及安全性研究

The Efficacy and Safety of Elderly Patients with Non Valvular Atrial Fibrillation:Application of Anticoagulation Therapy with Warfarin

目的探究高龄非瓣膜病性房颤应用华法林抗凝治疗的疗效及安全性。方法选取2013年7月—2015年7月收治的65例≥80岁非瓣膜病性房颤患者作为研究对象,将其随机分为两组,分别是华法林组与阿司匹林组,分别给予华法林抗凝治疗与阿司匹林药物治疗,对比两组疗效及安全性。结果阿司匹林组的终点事件发生率(28.13%)明显高于华法林组的终点事件发生率(6.06%),其差异有统计学意义(P<0.05)。阿司匹林组的出血发生率(12.50%)与华法林组的出血发生率(15.15%),差异无统计学意义(P>0.05)。结论针对高龄非瓣膜病性房颤中通过华法林抗凝治疗方式治疗,能够有效降低终点事件的发生率,并且治疗中出血发生率相对较低,疗效好,安全性高,具有一定的推广应用价值。

Objective To explore non-valvular atrial fibrillation elderly warfarin anticoagulation efficacy and safety.Methods July 2013—July 2015 65 patients ≥80 years of age treated with non-valvular atrial fibrillation patients as research subjects were randomly divided into two groups, namely warfarin and aspirin were given Hua warfarin anticoagulation therapy with aspirin therapy, compared two groups of efficacy and safety. Results Of the end of the aspirin group event rate（28.13%） was significantly higher than in the warfarin group endpoint event rate（6.06%）, the difference was statistically significant（P〈0.05）. The incidence of bleeding in the aspirin group（12.50%） and bleeding rates（15.15%） warfarin group had no significant difference not statistically significant（P〉0.05）. Conclusion For elderly non-valvular atrial fibrillation by warfarin therapy treatment can effectively reduce the incidence of endpoint events,and the treatment of the relatively low incidence of bleeding, effective, safe, it has a certain application value.